Year-end review

Home>Tag:Year-end review
Jan 11 2024

Halberd Corporation 2023 Year-End CEO Update and 2024 Goals

By |2024-01-10T20:13:22-05:00January 11th, 2024|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 11, 2024 -- Halberd Corporation (OTC: HALB) made significant advances in its technology development and accomplished major business goals during the second half of 2023. 2023 ACHIEVEMENTS Halberd received from the CDC two sets of antibiotic resistant bacteria and fungi (a total of 60 samples) on which to test its proprietary ...

Jan 3 2023

Halberd Corporation 2022 Year End CEO Letter and 2023 Goals

By |2023-01-02T20:07:25-05:00January 3rd, 2023|Featured, Investor News, Press Releases, Update Letter|0 Comments

Profound Advancements Explained Jackson Center, PA, January 3, 2023 -- Halberd Corporation (OTC: HALB) The second half of 2022 was a very busy time. 2022 2nd HALF ACHIEVEMENTS Halberd’s previous research on development of a monoclonal antibody (mAb) against COVID-19 (SARS-COV-2) was found to enhance the effectiveness of the leading commercial COVID antibody by 44.4%. ...

Go to Top